Lüneburg, Germany, 05 December 2022.
As an early adopter, Novo Nordisk and Körber are working closely on the development and deployment of PAS-X MES 3.3 to ensure the success of this cutting-edge program. So far, this close partnership has enabled PAS-X MES to be on a massive scale already.
With PAS-X MES 3.3 at the center of Novo Nordisk’s Pharma 4.0 digital ecosystem, the company will be able to bring best-of-breed applications with out-of-the-box capabilities tailored to GMP production to manufacturing sites across the world – globally empowering workforces and increasing manufacturing productivity.
Körber has developed PAS-X MES 3.3 as a solution that will continue to evolve with market needs through a continuous evolution stream support model that will allow Novo Nordisk to continuously bring new functionality into production. This approach to application lifecycle management ensures that the company’s systems can adapt as technology continues to improve while still meet productivity demands today. By leveraging the integrated intelligence and analytics products, Novo Nordisk ensures to get the most out of their manufacturing data to further drive efficiencies.
